human dhodh

DHODH-IN-8 has antimalarial activity. DHODH-IN-8 is an inhibitor of human and Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) with IC50 of 0.13 μM and 47.4 μM, and Kis of 0.016 μM and 5.6 μM, respectively.

Vidofludimus (SC12267) (4SC-101, SC12267) is a novel small molecule inhibitor of dihydroorotate dehydrogenase (DHODH).

hDHODH-IN-3 is an inhibitor of human dihydroorotate dehydrogenase with a pMIC50 value of 8.6. hDHODH-IN-3 can inhibit measles virus replication.

DHODH-IN-4 is a human and Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) inhibitor. The IC50 values of PfDHODH and HsDHODH are 4 μM and 0.18 μM, respectively. DHODH-IN-4 has antimalarial activity.

hDHODH-IN-4 (DHODH-IN-5) is a potent inhibitor of human dihydrogen dehydrogenase (DHODH). For human recombinant DHODH, its pIC50 is 7.8. hDHODH-IN-4 inhibits measles virus replication with a pMIC50 of 8.8.

hDHODH-IN-7 (DHODH-IN-9) is a nitrogen-containing analog and is a human dihydrorotatory dehydrogenase inhibitor. hDHODH-IN-7 and pMIC50 of 7.4 have antiviral effects.

Olorofim(F-901318)is a novel selective antifungal compound targeting pyrimidine biosynthesis in mycobacteria, with inhibitory effect on Aspergillus fumigatus DHODH (IC50: 44 nM), but little inhibitory effect on human DHODH (>100 uM).Olorofim has good efficacy against a variety of pathogenic filamentous and dimorphic fungi, such as Penicillium spp, P. dermatitidis spp and Fusarium spp.

DHODH-IN-17 is a human DHODH inhibitor with an IC50 of 0.40 μM. DHODH-IN-17 is a 2- anilino nicotinic acid that can be used in the study of acute myeloid leukemia (AML).

Farudodstat (ASLAN003) is an orally active and potent inhibitor of DHODH (Human Dihydroorotate Dehydrogenase) with antitumor activity, showing potential as a first-in-class candidate in AML [Acute Myeloid Leukemia].

DHODH-IN-3 is an effective inhibitor of human dihydroorotate dehydrogenase (HsDHODH) with IC50 value of 261 nM. DHODH-IN-3 binds to the ubiquinone binding cavity in DHODH with a Kiapp of 32 nM. DHODH-IN-3 has the potential to treat malaria.

hDHODH-IN-1 is a human dihydroorotate dehydrogenase (hDHODH) inhibitor exhibiting anti-inflammatory properties.

BAY-2402234 is an inhibitor of dihydroorotate dehydrogenase (DHODH) for the treatment of myeloid malignancies.BAY 2402234 is a selective low-nanomolar inhibitor of human DHODH enzymatic activity.

DHODH-IN-31 is a human dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 0.59 μM. DHODH-IN-31 exhibits antiviral activity, enabling research into infectious diseases such as SARS-CoV-2 and facilitating the development of antiviral therapeutics and mechanistic studies of nucleotide biosynthesis pathways in human cells.

DHODH-IN-28 (Compound 11a) is a potent fluorescent inhibitor targeting human dihydroorotate dehydrogenase (hDHODH) with an IC50 of 170 nM. It exhibits antileukemia and antiviral activities, and holds potential for research in cancer and infectious diseases.

DHODH-IN-30 (compound 4g) is a potent inhibitor of human dihydroorotate dehydrogenase (hDHODH), with an IC50 of 32 nM. Additionally, DHODH-IN-30 offers protective effects against oxidative stress.

BRD7539B is a Dihydroorotate dehydrogenase (DHODH) inhibitor . RD7539 shows to target PfDHODH (IC50 = 0.033 μM) selectively over human (Hs) DHODH (IC50 > 50 μM).

DHODH-IN-16 is an effective inhibitor of dihydroorotate dehydrogenase (DHODH, IC50 = 0.396 nM for human).

DHODH-IN-18 is a human DHODH inhibitor with an IC50 value of 0.2 nM.

Dhodh-in-20 (Compound 133) is a potent inhibitor of DHODH. Among them, DHODH is an iron-containing flavin-dependent enzyme that is present in the inner membrane of human mitochondria. DHODH-IN-20 showed an inhibitory effect on tumor growth. DHODH-IN-20 has the potential to be used in the study of acute myeloid leukemia.

hDHODH-IN-12 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), exhibiting an inhibitory concentration (IC50) of 0.421 μM. As the rate-limiting enzyme in the de novo synthesis of pyrimidines, critical for DNA/RNA synthesis, DHODH is localized within the inner membrane of human mitochondria. hDHODH-IN-12 is applicable in lung cancer research [1].

DHODH-IN-24 (compound 16) serves as a powerful inhibitor of human dihydroorotate dehydrogenase (DHODH), exhibiting an IC50 value of 91 nM [1].

DHODH-IN-25 (Compound 25) serves as an orally active inhibitor of dihydroorotate dehydrogenase (DHODH), exhibiting a potent IC50 of 5.4 nM against human DHODH. It is applicable in research related to acute myeloid leukemia (AML) [1].

PfDHODH-IN-2 is a dihydrothiophenone derivative, is a potent Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH, IC50 : 1.11 μM) inhibitor . It is used an antimalarial agent and can be used for the research of malaria

Tenovin-6-d6 is a deuterium-labeled version of Tenovin-6. This compound is an analog of Tenovin-1 and acts as an activator of p53 transcriptional activity. Tenovin-6 Hydrochloride inhibits the deacetylase activity of purified human SIRT1, SIRT2, and SIRT3 proteins, with IC50 values of 21 μM, 10 μM, and 67 μM, respectively. Additionally, Tenovin-6 can inhibit dihydroorotate dehydrogenase (DHODH).